Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in patients with advan...
Main Authors: | Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
by: Kraeber-Bodéré, F, et al.
Published: (2012) -
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
by: Leijen, S, et al.
Published: (2011) -
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
by: Leijen, S, et al.
Published: (2011) -
Challenges in nuclear medicine: innovative theranostic tools for personalized medicine
by: Françoise eKraeber-Bodéré, et al.
Published: (2014-07-01) -
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
by: Appels, N, et al.
Published: (2008)